RPRX Royalty Pharma plc

Price (delayed)

$40.33

Market cap

$24.48B

P/E Ratio

26.89

Dividend/share

$0.64

EPS

$1.5

Enterprise value

$29.6B

Highlights
RPRX's equity has surged by 91% year-on-year
The company's quick ratio has surged by 84% YoY and by 8% QoQ
The net income has plunged by 53% YoY
The P/E is 32% higher than the last 4 quarters average of 20.3

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
607.11M
Market cap
$24.48B
Enterprise value
$29.6B
Valuations
Price to earnings (P/E)
26.89
Price to book (P/B)
2.49
Price to sales (P/S)
7.16
EV/EBIT
26.57
EV/EBITDA
26.57
EV/Sales
13.49
Earnings
Revenue
$2.19B
EBIT
$1.11B
EBITDA
$1.11B
Free cash flow
$2.09B
Per share
EPS
$1.5
Free cash flow per share
$5.36
Book value per share
$16.2
Revenue per share
$5.63
TBVPS
$40.77
Balance sheet
Total assets
$15.91B
Total liabilities
$6.08B
Debt
$5.82B
Equity
$9.84B
Working capital
$2.16B
Liquidity
Debt to equity
0.59
Current ratio
9.44
Quick ratio
7.37
Net debt/EBITDA
4.59
Margins
EBITDA margin
50.8%
Gross margin
100%
Net margin
44.3%
Operating margin
66.7%
Efficiency
Return on assets
6.1%
Return on equity
13.7%
Return on invested capital
5.6%
Return on capital employed
7.1%
Return on sales
50.8%
Dividend
Dividend yield
1.59%
DPS
$0.64
Payout ratio
42.7%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
-0.07%
1 week
-0.54%
1 month
-4.41%
1 year
-5.97%
YTD
-19.42%
QTD
-1.61%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.19B
Gross profit
$2.19B
Operating income
$1.46B
Net income
$972.92M
Gross margin
100%
Net margin
44.3%
Royalty Pharma's net margin has shrunk by 59% YoY and by 3.5% QoQ
The net income has plunged by 53% YoY
The operating margin has dropped by 51% year-on-year and by 11% since the previous quarter
The operating income has contracted by 43% YoY and by 8% from the previous quarter

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
P/E
26.89
P/B
2.49
P/S
7.16
EV/EBIT
26.57
EV/EBITDA
26.57
EV/Sales
13.49
The P/E is 32% higher than the last 4 quarters average of 20.3
Royalty Pharma's EPS has increased by 14% QoQ
RPRX's equity has surged by 91% year-on-year
RPRX's P/B is 46% below its last 4 quarters average of 4.6
The revenue has increased by 17% YoY and by 3.4% from the previous quarter
The P/S is 14% below the last 4 quarters average of 8.3

Efficiency

How efficient is Royalty Pharma business performance
RPRX's ROE has plunged by 66% YoY and by 17% from the previous quarter
The ROA has plunged by 60% YoY and by 4.7% from the previous quarter
Royalty Pharma's return on sales has shrunk by 59% YoY and by 4.7% QoQ
The ROIC has shrunk by 56% YoY and by 5% QoQ

Dividends

What is RPRX's dividend history
DPS
$0.64
Dividend yield
1.59%
Payout ratio
42.7%
Recent dividends

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 162% more than its total liabilities
The current ratio has surged by 136% year-on-year and by 8% since the previous quarter
The company's quick ratio has surged by 84% YoY and by 8% QoQ
Royalty Pharma's debt is 41% lower than its equity
RPRX's equity has surged by 91% year-on-year
The debt to equity has decreased by 49% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.